Finance

Beta
Lists
532531:BOM
Strides Pharma Science Ltd
₹1,042.95
+1.52%
(+15.60) 1D
Jun 5, 3:51:09 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for 532531...
Open
₹1,041.70
High
₹1,049.30
Low
₹1,004.90
Mkt. cap
96.12B
Avg. vol.
13.17K
Volume
15.28K
P/E ratio
17.28
52-wk high
₹1,231.45
52-wk low
₹769.60
EPS
₹60.34
Shares outstanding
89.55M
No. of employees
3K
Open
₹1,041.70
High
₹1,049.30
Low
₹1,004.90
Mkt. cap
96.12B
Avg. vol.
13.17K
Volume
15.28K
P/E ratio
17.28
52-wk high
₹1,231.45
52-wk low
₹769.60
EPS
₹60.34
Shares outstanding
89.55M
No. of employees
3K
News stories
From sources across the web
Profile
Strides Pharma Science Limited is an Indian pharmaceutical company, headquartered at Bangalore. The company manufactures pharmaceutical products, over-the-counter drugs and nutraceuticals. Products include softgel capsules, hard-gel capsules, tablets and dry and wet injectables. The company has 15 manufacturing sites in six countries and marketing presence in 50 countries. The company partners with generic companies to supply retail and hospital generics in injectable products and softgels. The company's stock trades on the Bombay Stock Exchange and on the National Stock Exchange of India. Strides Arcolab changed name to Strides Shasun Ltd after an amalgamation of Shasun Pharmaceuticals with Strides Arcolab. In September 2014, the Board of Directors of both the companies had approved a scheme of amalgamation between the two companies. Arun Kumar is the founder and chairman, and has been on the board as managing director since its inception. Wikipedia
About Strides Pharma Science Ltd
CEO-
Employees3.3K
Founded1990
HeadquartersBengaluru, Karnataka, India
SectorPharmaceutical industry
Websitestrides.com
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
11.20B
12.21B
11.95B
13.23B
Cost of goods sold
4.44B
5.15B
4.63B
5.36B
Cost of revenue
4.44B
5.15B
4.63B
5.36B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.26B
2.27B
2.30B
2.47B
Operating expense
5.06B
5.24B
5.46B
6.01B
Total operating expenses
9.51B
10.39B
10.09B
11.37B
Operating income
1.69B
1.82B
1.85B
1.86B
Other non operating income
-388.77M
271.40M
1.07B
81.28M
EBT including unusual items
1.22B
1.53B
2.45B
1.48B
EBT excluding unusual items
1.30B
1.62B
2.49B
1.54B
Income tax expense
164.50M
215.93M
373.53M
187.70M
Effective tax rate
13.48%
14.10%
15.22%
12.68%
Other operating expenses
2.32B
2.47B
2.66B
3.00B
Net income
996.08M
1.28B
2.02B
1.27B
Net profit margin
8.90%
10.45%
16.92%
9.59%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-
-461.27M
-433.79M
-415.79M
Net interest expenses
-
-461.27M
-433.79M
-415.79M
Depreciation and amortization charges
488.86M
496.43M
506.23M
532.49M
EBITDA
2.09B
2.31B
2.25B
2.37B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer